EpilepsyRx

Prednisolone

Generic oral products; Orapred ODT

Limited use · infantile epileptic spasms syndrome (IESS)

Time-limited hormonal treatment for IESS under specialist supervision, followed by a taper. “Limited use” describes the treatment scope and duration; it is not an evidence rating. Prednisolone treatment of IESS is off-label in the United States.

Antiseizure use · off-label IESS treatment

Indication / use

Label / evidence summary
No U.S. antiseizure indication is listed in the reviewed DailyMed prednisolone label. Limited, off-label use for infantile epileptic spasms syndrome (IESS) is supported by the UKISS study; this is not a U.S. label indication.
Role
Limited-course therapy · off-label IESS treatment
Class
Hormonal therapy — systemic glucocorticoid

UKISS evidence and dosing checked 26 September 2026. The DailyMed PDF is general product labeling and does not establish an IESS indication. Study ages describe the trial population, not approved age limits.

Formulations & strengths

U.S. products unless another country is named. Strengths are per unit or stated volume.

Brand & formulation labels

Each link names the product and formulation it covers. Archived labels do not establish current availability.

Dosing & administration

Adult / product-specific schedule
No adult antiseizure regimen is described by UKISS.
Pediatric
UKISS oral prednisolone: 10 mg four times daily (40 mg/day) for 14 days; if spasms persisted after the first week, the second-week dose was 20 mg three times daily (60 mg/day). These are fixed daily doses, not mg/kg/day.
Titration / repeat dosing
After the 14-day treatment phase, taper: from 40 mg/day, 30 mg/day for 5 days, then 20 mg/day for 5 days, then 10 mg/day for 5 days, then stop; from 60 mg/day, 40 mg/day for 5 days, then 20 mg/day for 5 days, then 10 mg/day for 5 days, then stop. The treating specialist must prescribe and monitor the individual course and adrenal-suppression plan.
Dose basis
Historical UKISS trial protocol for IESS, not FDA-approved epilepsy dosing. This summary is not medical advice. Clinical and EEG reassessment and infection, blood-pressure, glucose and adrenal monitoring are required.

UKISS prednisolone regimen · off-label IESS use

Treatment phaseOral prednisolone dose
Days 1–710 mg four times daily = 40 mg/day
Days 8–14Continue 40 mg/day; if spasms persist after week 1, 20 mg three times daily = 60 mg/day
Taper after day 14 if taking 40 mg/day30 mg/day for 5 days → 20 mg/day for 5 days → 10 mg/day for 5 days → stop
Taper after day 14 if taking 60 mg/day40 mg/day for 5 days → 20 mg/day for 5 days → 10 mg/day for 5 days → stop

Fixed daily doses, not mg/kg/day. Historical study regimen; specialist prescribing and monitoring are essential. UKISS excluded tuberous sclerosis syndrome. See the linked original study and protocol evidence.

Practical administration

Product instructions
Oral prednisolone; verify the dispensed concentration and prescribe both mg and mL when using liquid. Prednisolone is not prednisone. Do not start, change or stop a steroid course without the treating team’s instructions.

Dose adjustment & concentrations

Renal impairment
No standard renal dose algorithm established; review product precautions and monitor clinical status.
Hepatic impairment
Individualize with specialist review; consult the exact product label.
Serum reference information
No established antiseizure therapeutic serum concentration target.

Safety

Boxed warning
No boxed warning in the linked label; substantial infection and adrenal risks with high-dose treatment.
Contraindications
Product hypersensitivity; systemic fungal infection is a contraindication in systemic oral-solution labeling. Avoid live vaccines during immunosuppressive corticosteroid treatment. Review other infection, GI and endocrine contraindications in the dispensed product label.
Serious precautions & monitoring
Before high-dose therapy, assess infection/varicella risk, blood pressure and glucose; monitor at least weekly blood pressure and glucose during IESS treatment, with weight and electrolytes as indicated. Provide steroid alert, adrenal-suppression/taper and intercurrent-illness plans. Watch GI bleeding, psychiatric changes, hypertension and hypokalemia.

Common / selected adverse effects

  • Increased appetite and weight gain
  • Irritability, insomnia and mood changes
  • Hypertension, edema and hyperglycemia
  • Infection and GI irritation
  • Adrenal suppression with withdrawal risk

Drug interactions: toxicity & clinical action

Partner / combinationClinical effectClinical action
Carbamazepine, phenytoin, phenobarbital or rifampinIncreased corticosteroid metabolism can reduce treatment effect.Review the hormone regimen and response with the specialist when adding/removing an inducer.
CYP3A4 inhibitors (azoles, macrolides)Increased corticosteroid exposure and endocrine/infection toxicity.Consider alternatives or dose adjustment; monitor glucose, blood pressure and adrenal effects.
NSAIDs / potassium-wasting agents / digoxinGI bleeding with NSAIDs; hypokalemia with diuretics can increase digoxin arrhythmia risk.Assess GI risk and electrolytes; avoid unnecessary combinations.
Live vaccines / diabetes medicines / warfarinInfection risk from live vaccines; hyperglycemia and variable anticoagulant response.Avoid live vaccines at immunosuppressive doses; monitor glucose and INR and adjust therapy.

Pregnancy & contraception

Fetal / neonatal risk
Maternal systemic prednisolone may affect fetal growth and cause neonatal adrenal suppression. Reports of first-trimester orofacial clefts are inconsistent. This is distinct from administering a short IESS course directly to the infant.
Pregnancy / postpartum monitoring
After substantial maternal exposure, observe the newborn for adrenal insufficiency.

Clinical evidence

Research summaries describe studied populations and outcomes; they do not add indications or constitute treatment recommendations.

Direct pivotal trial Guideline-supported off-label use

Trial summary

Study design / duration
UKISS (2004): multicentre randomized trial of hormonal treatment versus vigabatrin; 107 infants enrolled, including 30 assigned prednisolone. Primary assessment at days 13–14; follow-up publication at age 14 months.
Primary endpoint
Primary UKISS endpoint: no spasms on days 13 and 14. Clinical and EEG response are distinct assessments.
Results
Pooled hormonal treatment: 40/55 (73%) versus vigabatrin: 28/52 (54%); absolute difference 19 percentage points. The hormonal group included both prednisolone and tetracosactide.
Confidence intervals
Hormonal treatment versus vigabatrin: 95% CI for the absolute difference, 1–36 percentage points; p=0.043. This is not a prednisolone-only estimate.
Discontinuations
Adverse events occurred in 55% of the hormonal-treatment group and 54% of the vigabatrin group; these are not withdrawal rates.
Exposure duration
UKISS: 14-day treatment phase followed by a reducing prednisolone course. The 2005 publication reports developmental and epilepsy outcomes at age 14 months.
Seizure freedom
UKISS: 21/30 infants assigned prednisolone (70%) had no spasms on days 13–14. This descriptive subgroup result does not establish equivalence to ACTH or a particular commercial formulation.

Trial publications

Comparative evidence

Findings
See the linked syndrome guidance and studies; do not infer equivalent efficacy across different hormone products, doses or syndromes.

Mechanism of action

  • Prednisolone activates intracellular glucocorticoid receptors and alters gene transcription, with anti-inflammatory and immunosuppressive effects. It is the active glucocorticoid; prednisone is a different prodrug.
  • The specific mechanism suppressing epileptic spasms or sleep-activated epileptic activity remains incompletely defined; it is not direct GABA-A positive allosteric modulation.

Pharmacology

Adult values unless specified. Vd/F denotes apparent oral distribution volume.

Pharmacokinetics

Bioavailability
Readily absorbed orally. Orapred ODT and Pediapred solution produced comparable exposure in a 30 mg adult study; an absolute percentage is not provided in the cited U.S. label.
Elimination half-life
Mean plasma half-life approximately 2.6 ± 0.27 hours (Orapred ODT label). Biological/glucocorticoid effects persist beyond the plasma half-life.
Volume of distribution
Approximately 0.22–0.7 L/kg.
Active metabolite(s)
No additional clinically established active metabolite is identified in the cited labeling. Prednisolone is itself an active glucocorticoid.
Active-metabolite half-life
Not applicable to an established additional active metabolite.
Protein binding
Approximately 70–90%, concentration-dependent.
Metabolism / elimination
Primarily hepatic metabolism; urinary sulfate and glucuronide conjugates.

Plasma clearance does not determine the duration of steroid effects, adrenal suppression or the taper schedule.

Molecular structure

Molecular structure of Prednisolone
Principal compound; salt and product forms may differ.
NIH PubChem structure and record ↗

Product history

Initial U.S. approval
U.S. prednisolone products have FDA labeling; epilepsy indications in this profile are off-label.
Market / formulation history
Availability varies by product and jurisdiction.
Brands
Generic oral products; Orapred ODT
Manufacturer / marketer
Generic oral products; Orapred ODT
Generic availability
Product-dependent.
Related drugs
See mechanism and syndrome guidance.

Sources & review status

Representative sources are selected product labels, not an exhaustive list of generic manufacturers. Consult the exact product and formulation prescribed. Brand-name package inserts are linked separately.

Brand reference: Orapred ODT ↗

Orapred ODT is a formulation-specific brand insert. It does not establish an IESS indication or the UKISS regimen.

Off-label IESS evidence and UKISS regimen checked: 2026-09-26. Other profile sources reviewed: 2026-09-15 · label revision noted at that review: See linked product label. This is a draft reference; final review is pending.

Send a comment · Privacy & traffic measurement